India Glycols Limited has informed the Exchange regarding Update on NCLT Hearing''.

Regulatory & Legal View source PDF Explain this filing

INDIAGLYCO · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reactionminutes from the announcement price · days from the prior close

-0.6%Reaction day

₹991.40

prior close

₹1008.20

announcement price

After-mkt

timing

Nifty Microcap 250market · index membership as recorded later (tracked since Jun 2026)+0.1%-0.7% vs market

Breweries & Distilleries peers, median of 25sector-0.2%-0.4% vs sector

On the reaction day the stock moved 0.7 pts less than Nifty Microcap 250 and 0.4 pts less than its Breweries & Distilleries peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.

Minutes after the announcementfrom the announcement price · no benchmark

Stock

-0.3

10m

-0.8

15m

-0.5

30m

-0.5

Sessions after the filingfrom the prior close

StockMarketvs marketSectorvs sector

Reaction day

-0.6+0.1-0.7-0.2-0.4

Next day

+1.5+1.7-0.2+1.1+0.4

+1.7+2.4-0.7+1.2+0.5

+1.1+2.4-1.3+0.7+0.4

-1.2+1.7-2.9-0.1-1.1

+0.2+0.6-0.4-2.0+2.2

-0.6+1.9-2.6-2.0+1.4

15d

-1.6+4.9-6.4-0.4-1.2

-3.7+8.9-12.6+0.7-4.4

+15.0+7.5+7.5-2.5+17.5

+20.4+13.6+6.8-6.6+27.0

UpDownMarket · Nifty Microcap 250Sector · Breweries & Distilleries peers, median of 25Pending

Minute windows have no benchmark: there is no intraday index history to compare against.

AI summary

India Glycols Limited has provided an update on the NCLT hearing regarding its Scheme of Arrangement involving a demerger into Ennature Biopharma Limited and IGL Spirits Limited. The matter was listed for hearing on 21st May 2026 but could not be taken up due to paucity of time. The next hearing date is yet to be notified. This is a routine procedural update in an ongoing corporate restructuring process.

Likely market impact

The postponement of the NCLT hearing delays the demerger process but does not indicate any adverse development. Shareholders should await further updates on the next hearing date.